TY - JOUR
T1 - Serum cholesterol and risk of lower urinary tract symptoms progression
T2 - Results from the Reduction by Dutasteride of Prostate Cancer Events study
AU - Feng, Tom
AU - Howard, Lauren E.
AU - Vidal, Adriana C.
AU - Moreira, Daniel M.
AU - Castro-Santamaria, Ramiro
AU - Andriole, Gerald L.
AU - Freedland, Stephen J.
N1 - Funding Information:
The REDUCE study was funded by GlaxoSmithKline. Ramiro Castro-Santamaria was an employee of GlaxoSmithKline. Dr Andriole was consultant of GlaxoSmithKline.
Publisher Copyright:
© 2016 The Japanese Urological Association
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Objective: To determine if cholesterol is a risk factor for the development of lower urinary tract symptoms in asymptomatic men. Methods: A post-hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was carried out in 2323 men with baseline International Prostate Symptom Score <8 and not taking benign prostatic hyperplasia or cholesterol medications. Cox proportion models were used to test the association between cholesterol, high-density lipoprotein, low-density lipoprotein and the cholesterol : high-density lipoprotein ratio with incident lower urinary tract symptoms, defined as first report of medical treatment, surgery or two reports of an International Prostate Symptom Score >14. Results: A total of 253 men (10.9%) developed incident lower urinary tract symptoms. On crude analysis, higher high-density lipoprotein was associated with a decreased lower urinary tract symptoms risk (hazard ratio 0.89, P = 0.024), whereas total cholesterol and low-density lipoprotein showed no association. After multivariable adjustment, the association between high-density lipoprotein and incident lower urinary tract symptoms remained significant (hazard ratio 0.89, P = 0.044), whereas no association was observed for low-density lipoprotein (P = 0.611). There was a trend for higher cholesterol to be linked with higher lower urinary tract symptoms risk, though this was not statistically significant (hazard ratio 1.04, P = 0.054). A higher cholesterol : high-density lipoprotein ratio was associated with increased lower urinary tract symptoms risk on crude (hazard ratio 1.11, P = 0.016) and adjusted models (hazard ratio 1.12, P = 0.012). Conclusions: Among asymptomatic men participating in the REDUCE study, higher cholesterol was associated with increased incident lower urinary tract symptoms risk, though the association was not significant. A higher cholesterol : high-density lipoprotein ratio was associated with increased incident lower urinary tract symptoms, whereas higher high-density lipoprotein was protective. These findings suggest dyslipidemia might play a role in lower urinary tract symptoms progression.
AB - Objective: To determine if cholesterol is a risk factor for the development of lower urinary tract symptoms in asymptomatic men. Methods: A post-hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was carried out in 2323 men with baseline International Prostate Symptom Score <8 and not taking benign prostatic hyperplasia or cholesterol medications. Cox proportion models were used to test the association between cholesterol, high-density lipoprotein, low-density lipoprotein and the cholesterol : high-density lipoprotein ratio with incident lower urinary tract symptoms, defined as first report of medical treatment, surgery or two reports of an International Prostate Symptom Score >14. Results: A total of 253 men (10.9%) developed incident lower urinary tract symptoms. On crude analysis, higher high-density lipoprotein was associated with a decreased lower urinary tract symptoms risk (hazard ratio 0.89, P = 0.024), whereas total cholesterol and low-density lipoprotein showed no association. After multivariable adjustment, the association between high-density lipoprotein and incident lower urinary tract symptoms remained significant (hazard ratio 0.89, P = 0.044), whereas no association was observed for low-density lipoprotein (P = 0.611). There was a trend for higher cholesterol to be linked with higher lower urinary tract symptoms risk, though this was not statistically significant (hazard ratio 1.04, P = 0.054). A higher cholesterol : high-density lipoprotein ratio was associated with increased lower urinary tract symptoms risk on crude (hazard ratio 1.11, P = 0.016) and adjusted models (hazard ratio 1.12, P = 0.012). Conclusions: Among asymptomatic men participating in the REDUCE study, higher cholesterol was associated with increased incident lower urinary tract symptoms risk, though the association was not significant. A higher cholesterol : high-density lipoprotein ratio was associated with increased incident lower urinary tract symptoms, whereas higher high-density lipoprotein was protective. These findings suggest dyslipidemia might play a role in lower urinary tract symptoms progression.
KW - benign prostatic hyperplasia
KW - cholesterol
KW - lipids
KW - lower urinary tract symptoms
UR - http://www.scopus.com/inward/record.url?scp=85006988130&partnerID=8YFLogxK
U2 - 10.1111/iju.13265
DO - 10.1111/iju.13265
M3 - Article
C2 - 28004415
AN - SCOPUS:85006988130
SN - 0919-8172
VL - 24
SP - 151
EP - 156
JO - International Journal of Urology
JF - International Journal of Urology
IS - 2
ER -